Erythropoietin reduces the expression of myostatin in mdx dystrophic mice

Página do item simplificado
dc.contributor.authorFeder, David
dc.contributor.authorRugollini, M.
dc.contributor.authorSantomauro, A.
dc.contributor.authorOliveira, Luciano P.
dc.contributor.authorLioi, V. P.
dc.contributor.authorSantos, Rosangela Aparecida dos
dc.contributor.authorFerreira, Leonardo G.
dc.contributor.authorNunes, Maria Tereza
dc.contributor.authorCarvalho, Maria Helena
dc.contributor.authorDelgado, Pilar O.
dc.contributor.authorCarvalho, Alzira A. S.
dc.contributor.authorFonseca, Fernando Luiz Affonso [UNIFESP]
dc.contributor.institutionFac Med ABC
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T14:38:03Z
dc.date.available2016-01-24T14:38:03Z
dc.date.issued2014-11-01
dc.description.abstractErythropoietin (EPO) has been well characterized as a renal glycoprotein hormone regulating red blood cell production by inhibiting apoptosis of erythrocyte progenitors in hematopoietic tissues. EPO exerts regulatory effects in cardiac and skeletal muscles. Duchenne muscular dystrophy is a lethal degenerative disorder of skeletal and cardiac muscle. in this study, we tested the possible therapeutic beneficial effect of recombinant EPO (rhEPO) in dystrophic muscles in mdx mice. Total strength was measured using a force transducer coupled to a computer. Gene expression for myostatin, transforming growth factor-beta 1 (TGF-beta 1), and tumor necrosis factor-alpha (TNF-alpha) was determined by quantitative real time polymerase chain reaction. Myostatin expression was significantly decreased in quadriceps from mdx mice treated with rhEPO (rhEPO = 0.60 +/- 0.11, control= 1.07 +/- 0.11). On the other hand, rhEPO had no significant effect on the expression of TGF-beta 1 (rhEPO = 0.95 +/- 0.14, control= 1.05 +/- 0.16) and TNF-alpha (rhEPO = 0.73 +/- 0.20, control= 1.01 +/- 0.09). These results may help to clarify some of the direct actions of EPO on skeletal muscle.en
dc.description.affiliationFac Med ABC, BR-09060650 Santo Andre, SP, Brazil
dc.description.affiliationUniv São Paulo, Inst Ciencias Biomed, BR-05508 São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Inst Ciencias Quim Ambientais & Farmaceut, Diadema, SP, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Inst Ciencias Quim Ambientais & Farmaceut, Diadema, SP, Brazil
dc.description.sourceWeb of Science
dc.format.extent966-971
dc.identifierhttp://dx.doi.org/10.1590/1414-431X20143858
dc.identifier.citationBrazilian Journal of Medical and Biological Research. São Paulo: Assoc Bras Divulg Cientifica, v. 47, n. 11, p. 966-971, 2014.
dc.identifier.doi10.1590/1414-431X20143858
dc.identifier.fileS0100-879X2014001100966.pdf
dc.identifier.issn0100-879X
dc.identifier.scieloS0100-879X2014001100966
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/38368
dc.identifier.wosWOS:000343748800006
dc.language.isoeng
dc.publisherAssoc Bras Divulg Cientifica
dc.relation.ispartofBrazilian Journal of Medical and Biological Research
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectMuscular dystrophyen
dc.subjectErythropoietinen
dc.subjectMyostatinen
dc.subjectSkeletal muscleen
dc.subjectQuadricepsen
dc.titleErythropoietin reduces the expression of myostatin in mdx dystrophic miceen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
S0100-879X2014001100966.pdf
Tamanho:
159.13 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
ICAQF - Artigos